Promising results for Swedish cancer drug candidate

A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.

Qigong can help fight fatigue in prostate cancer survivors

The flowing movements and meditative exercises of the mind-body activity Qigong may help survivors of prostate cancer to combat fatigue. These are the findings of a trial study led by Dr. Anita Y. Kinney at the University of New Mexico Cancer Center and Dr. Rebecca Campo at the University of North Carolina at Chapel Hill. The study took place at the Huntsman Cancer Institute at the University of Utah, and was published in Springer’s Journal of Cancer Survivorship.

Severe fatigue is one of the most common cancer-related symptoms reported by cancer survivors, particularly for prostate cancer survivors receiving androgen deprivation therapy (ADT). This subjective sense of physical, emotional or cognitive exhaustion may persist for months or years following treatment. It greatly diminishes survivors' quality of life by limiting their ability to perform daily activities and causes significant distress.

Maximizing Broccoli's Cancer-Fighting Potential

Spraying a plant hormone on broccoli — already one of the planet’s most nutritious foods — boosts its cancer-fighting potential, and researchers say they have new insights on how that works. They published their findings, which could help scientists build an even better, more healthful broccoli, in ACS’ Journal of Agricultural & Food Chemistry.

Genetic errors identified in 12 major cancer types

Examining 12 major types of cancer, scientists at Washington University School of Medicine in St. Louis have identified 127 repeatedly mutated genes that appear to drive the development and progression of a range of tumors in the body. The discovery sets the stage for devising new diagnostic tools and more personalized cancer treatments. 

The research, published Oct. 17 in Nature, shows that some of the same genes commonly mutated in certain cancers also occur in seemingly unrelated tumors. For example, a gene mutated in 25 percent of leukemia cases in the study also was found in tumors of the breast, rectum, head and neck, kidney, lung, ovary and uterus.